SynlogicSYBX
About: Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Employees: 6
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0.93% less ownership
Funds ownership: 59.28% [Q2] → 58.34% (-0.93%) [Q3]
2% less capital invested
Capital invested by funds: $10.4M [Q2] → $10.2M (-$241K) [Q3]
6% less funds holding
Funds holding: 17 [Q2] → 16 (-1) [Q3]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for SYBX.
Financial journalist opinion
